INNOVADERM CRO IS NOW INDERO.
READ THE ANNOUNCEMENT
Talk to us

“Collaborative Excellence: A Testament to our Shared Success with Innovaderm!” – A Ventyx Biosciences Testimonial

Ana Palijan, PhD

Ana Palijan, PhD

Director, Early Phase and Translational Research

Author picture

Innovaderm is excited to share a glowing testimonial from Ventyx Biosciences!

“We would like to express our gratitude for the exceptional partnership we’ve had with Innovaderm. Our collaboration on a phase 2 study for moderate to severe plaque psoriasis was nothing short of remarkable. The expertise and motivation Innovaderm brought to the table were pivotal to our success. From the initial synopsis development to the final stages of study conduct, the synergy between our teams was palpable and was underpinned by Innovaderm’s strong relationships with sites, investigators and KOLs. The robust collaboration Innovaderm has established within the dermatology field instilled a deep sense of trust in us. This trust was reflected in the flawless execution of the study, which both teams can look back on with pride.”
Snehal Naik, Senior Vice President of Clinical Development at Ventyx Biosciences

Congratulations to our incredible team for earning high praise from another satisfied customer!

Our dedication to providing tailored solutions and fostering strong relationships continues to shine through in testimonials like these.

SHARE THIS POST

Subscribe to our newsletter.

Do not miss out on valuable insights and research updates. Join our scientific community today!

This field is for validation purposes and should be left unchanged.
Talk to us

Jeff Smith

Chef de la direction

Jeff Smith, Chef de la direction d’Indero Recherches, apporte prĂšs de 30 ans d’expĂ©rience dans l’industrie pharmaceutique et CRO, s’Ă©tant distinguĂ© par son leadership exceptionnel, sa vision stratĂ©gique et son innovation. L’expertise de Jeff couvre des opĂ©rations mondiales, la gestion de la croissance, ainsi que la promotion d’une culture d’entreprise collaborative. Ses atouts en matiĂšre de crĂ©ation de valeur, de gestion des partenaires et d’opĂ©rations CRO ont toujours contribuĂ© au succĂšs dans ses fonctions prĂ©cĂ©dentes. Sous la direction de Jeff, Indero continue d’étendre ses capacitĂ©s, faisant progresser les connaissances mĂ©dicales et les nouvelles thĂ©rapies en dermatologie et en rhumatologie.

Revolutionize Your Topical Trials

Efficacy insights in days, not months.

 Indero’s Early Phase 1 model enables sponsors to initiate topical studies that detect early pharmacodynamic signals much sooner than traditional phase 1, using microdosing and transcriptomic analysis. This approach reduces preclinical requirements, shortens study duration from 8–12 weeks to ≀3 days, and lowers costs, helping teams make informed go/no-go decisions faster.
LEARN MORE >